ACADIA Pharmaceuticals Stock Forecast, Price & News

+0.18 (+0.70 %)
(As of 06/18/2021 05:07 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.64 million shs
Average Volume2.01 million shs
Market Capitalization$4.17 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACADIA Pharmaceuticals logo

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.73 out of 5 stars

Medical Sector

255th out of 2,100 stocks

Pharmaceutical Preparations Industry

122nd out of 831 stocks

Analyst Opinion: 3.2Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

Is ACADIA Pharmaceuticals a buy right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 13 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ACADIA Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View analyst ratings for ACADIA Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than ACADIA Pharmaceuticals?

Wall Street analysts have given ACADIA Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ACADIA Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a drop in short interest during the month of May. As of May 28th, there was short interest totaling 5,800,000 shares, a drop of 20.0% from the May 13th total of 7,250,000 shares. Based on an average daily volume of 2,220,000 shares, the days-to-cover ratio is presently 2.6 days. Currently, 3.6% of the shares of the stock are sold short.
View ACADIA Pharmaceuticals' Short Interest

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for ACADIA Pharmaceuticals

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its earnings results on Tuesday, May, 4th. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the Zacks' consensus estimate of ($0.53) by $0.11. The biopharmaceutical company had revenue of $106.55 million for the quarter, compared to the consensus estimate of $112.91 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 41.17% and a negative net margin of 56.74%.
View ACADIA Pharmaceuticals' earnings history

How has ACADIA Pharmaceuticals' stock been impacted by COVID-19?

ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ACAD shares have decreased by 29.4% and is now trading at $26.02.
View which stocks have been most impacted by COVID-19

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals issued an update on its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $510 million-$550 million, compared to the consensus revenue estimate of $535.93 million.

What price target have analysts set for ACAD?

19 Wall Street analysts have issued twelve-month price targets for ACADIA Pharmaceuticals' stock. Their forecasts range from $18.00 to $57.00. On average, they expect ACADIA Pharmaceuticals' share price to reach $31.35 in the next twelve months. This suggests a possible upside of 20.5% from the stock's current price.
View analysts' price targets for ACADIA Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the following people:
  • Mr. Stephen R. Davis, CEO & Director (Age 60, Pay $1.23M)
  • Dr. Srdjan R. Stankovic, Pres (Age 64, Pay $1.12M)
  • Ms. Elena H. Ridloff C.F.A., CFA, Exec. VP & CFO (Age 41, Pay $646.54k)
  • Mr. Austin D. Kim, Exec. VP, Gen. Counsel & Sec. (Age 57, Pay $626.76k)
  • Mr. James K. Kihara, VP, Corp. Controller & Principal Accounting Officer (Age 41)
  • Mr. Bob Mischler, Sr. VP of Strategy & Technology Operations
  • Mr. Mark C. Johnson, VP of Investor Relations
  • Ms. Stephanie Fagan, Sr. VP of Corp. Affairs & Chief Communications Officer
  • Ms. Charmaine Lykins, Sr. VP of Global Product Planning & Chief Marketing Officer
  • Dr. Mary Ellen Turner, Sr. VP of Pharmacovigilance & Corp. Safety Officer

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals CEO Steve Davis on Steve Davis has an approval rating of 88% among ACADIA Pharmaceuticals' employees.

Who are some of ACADIA Pharmaceuticals' key competitors?

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baker BROS. Advisors LP (26.16%), Price T Rowe Associates Inc. MD (5.22%), BlackRock Inc. (4.62%), Janus Henderson Group PLC (3.36%), Fred Alger Management LLC (1.74%) and Ameriprise Financial Inc. (1.52%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends for ACADIA Pharmaceuticals

Which major investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Great Point Partners LLC, PFM Health Sciences LP, UBS Asset Management Americas Inc., Allianz Asset Management GmbH, Polar Capital Holdings Plc, Ensign Peak Advisors Inc, and Cubist Systematic Strategies LLC. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Elena Ridloff, Michael J Yang, Srdjan R Stankovic, and Stephen Davis.
View insider buying and selling activity for ACADIA Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Ameriprise Financial Inc., Federated Hermes Inc., Voloridge Investment Management LLC, Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, Fred Alger Management LLC, and Woodline Partners LP.
View insider buying and selling activity for ACADIA Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $26.02.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals has a market capitalization of $4.17 billion and generates $441.76 million in revenue each year. The biopharmaceutical company earns $-281,580,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

ACADIA Pharmaceuticals employs 640 workers across the globe.

What is ACADIA Pharmaceuticals' official website?

The official website for ACADIA Pharmaceuticals is

Where are ACADIA Pharmaceuticals' headquarters?

ACADIA Pharmaceuticals is headquartered at 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.